Form D · Other
Persevere Therapeutics Inc.
Chesterbrook, PA · CIK 0002115419
Offering snapshot reported Mar 4, 2026 · SEC filing
- Reported sold
- $1.57M Offering amount: $5M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 11, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 4, 2026 | Initial | $1,574,999 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-575357
Source: Form D, filed Mar 4, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Greg Bosch | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
851 Duportail Road, 2 Nd Floor
Chesterbrook, PA, 19087
Chesterbrook, PA, 19087